Albaron Partners Completes Sale of Beyond Podiatry to CUC Inc. (TSE: 9158)

New York, NY, January 5, 2024 - Albaron Partners LP ("Albaron"), a middle market private equity firm, is pleased to announce that it has completed the sale of Albaron Podiatry Holdings LLC d/b/a Beyond Podiatry, the Midwest's leading podiatric medicine practice management company, to CUC Inc. (TSE: 9158). The transaction values the business at $87 million and represents the first acquisition for CUC Inc. in the U.S. as well as the first private equity exit in U.S. podiatry.

"This is a transformational moment for Beyond Podiatry. We are thrilled for Dr. Stephen Frascone and his fellow physician shareholders, as well as John Moroney, President, and the entire Beyond Podiatry team," said Alessio Baraldi, Albaron Partners. "CUC is the perfect partner for the platform's next stage of growth, and we look forward to following Beyond Podiatry's continued success."

"I could not have wished for a better first partnership than what we built with Albaron," said Dr. Frascone, founder and Chief Medical Officer of Beyond Podiatry. "Their strategic direction, operational expertise and vision for growth is unparalleled in the healthcare middle market."

With over 200 employees across 30+ locations in the Midwest, Beyond Podiatry treats more than 250,000 patients per year. Since its founding in 2018, it has consistently expanded through M&A and de novo clinic openings, supporting a team of 56 doctors across Michigan, Illinois, Ohio, Kentucky, and Indiana.

Founded in 2017, Albaron is an operationally focused middle market healthcare private equity firm whose dedicated team of healthcare investors and operators helps physician founders and management teams scale their businesses.